VTRS vs. TAK, GMAB, ALNY, TEVA, RPRX, BMRN, BGNE, UTHR, RDY, and SRPT
Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Takeda Pharmaceutical (TAK), Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Viatris (NASDAQ:VTRS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
Takeda Pharmaceutical has a net margin of 6.18% compared to Viatris' net margin of -0.37%. Viatris' return on equity of 16.63% beat Takeda Pharmaceutical's return on equity.
Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 4.6%. Takeda Pharmaceutical pays an annual dividend of $0.26 per share and has a dividend yield of 1.9%. Viatris pays out -800.0% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 47.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.
Takeda Pharmaceutical received 79 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 35.59% of users gave Viatris an outperform vote.
Viatris has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Viatris currently has a consensus price target of $11.00, suggesting a potential upside of 5.06%. Takeda Pharmaceutical has a consensus price target of $14.00, suggesting a potential upside of 3.93%. Given Viatris' higher probable upside, analysts clearly believe Viatris is more favorable than Takeda Pharmaceutical.
Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Viatris and Viatris both had 4 articles in the media. Takeda Pharmaceutical's average media sentiment score of 0.73 beat Viatris' score of 0.00 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.
79.9% of Viatris shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Takeda Pharmaceutical beats Viatris on 9 of the 17 factors compared between the two stocks.
Get Viatris News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
